Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Jefferies analyst Biren Amin reiterated his Buy rating and $43 price target on The Medicines Company (NASDAQ: MDCO) saying Alnylam Pharmaceuticals (NASDAQ: ALNY) set back has no read-through to the company's PCSK9 Program.
Amin commented, "ALNY announced that revusiran was stopped due to lack of a treatment benefit w/ an imbalance of deaths favoring the revusiran arm over placebo. The imbalance was not tx-related. As a result of ALNY's update, MDCO provided a safety update on ALN-PCSsc in which it reported no imbalances to date on peripheral neuropathy, liver toxicity, renal toxicity, and mortality from its 501-patient ORION-1 study. Data from this trial are expected at AHA on Nov 15."
MDCO last traded down 10.4% in pre-open trade to $34.50.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dycom Industries (DY) Weakness Tied to Reduced Expansion Plans at Google Fiber (GOOG) (GOOGL) (MTZ)
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
- Graphic Packaging (GPK) PT, Estimates Trimmed at Jefferies Post Q3
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Hot Comments, Trader Talk
Related EntitiesJefferies & Co, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!